Andarix Pharmaceuticals’ Targeted Therapy Demonstrates Efficacy in Pancreatic Cancer

Tozaride Demonstrates Pancreatic Tumor Reduction in Animal Model ANDARIX Pharmaceuticals, a clinical stage company, announced today the publication of research findings that demonstrate the ability of its Tozaride targeted peptide therapy to reduce the size of pancreatic cancer tumors. The research paper titled “The Somatostatin Analog Rhenium Re-188-P2045 Inhibits the Growth of AR42J Pancreatic Tumor-Xenografts”…

Read More

Andarix Pharmaceuticals Selected to Present at International Drug Conference in Copenhagen

ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for small cell lung and other cancers announced that its Chief Executive Officer, Chris Adams, will present at the Orphan Drugs Summit to be held in Copenhagen, Denmark from September 17-19, 2014. Conference agenda information are available at www.orphandrugssummit.com. Mr. Adams will highlight recent results…

Read More

Andarix Pharmaceuticals Receives Pancreatic Cancer Orphan Drug Designation from the FDA

Targeted therapy for pancreatic cancer is based on personalized medicine approach ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung cancer announced today that Tozaride, the Company’s lead candidate for targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the…

Read More

Andarix Receives Orphan Drug Designation from the FDA for Small Cell Lung Cancer

Novel Targeted and Personalized Medicine Approach to Lung Cancer ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancers announced today that Tozaride, the Company’s targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small…

Read More